Canadian Stroke Best Practice Recommendations, seventh edition: Acetylsalicylic acid for prevention of vascular events

Theodore Wein; M. Patrice Lindsay; David J. Gladstone; Alexandre Poppe; Alan Bell; Leanne K. Casaubon; Norine Foley; Shelagh B. Coutts; Jafna Cox; James Douketis; Thalia Field; Laura Gioia; Jeffrey Habert; Eddy Lang; Shamir R. Mehta; Christine Papoushek; William Semchuk; Mikul Sharma; Jacob A. Udell; Stephanie Lawrence; Anita Mountain; Gord Gubitz; Dar Dowlatshahi; Anne Simard; Andrea de Jong; Eric E. Smith

doi:10.1503/cmaj.191599

Canadian Stroke Best Practice Recommendations, seventh edition: Acetylsalicylic acid for prevention of vascular events

Theodore Wein, M. Patrice Lindsay, David J. Gladstone, Alexandre Poppe, Alan Bell, Leanne K. Casaubon, Norine Foley, Shelagh B. Coutts, Jafna Cox, James Douketis, Thalia Field, Laura Gioia, Jeffrey Habert, Eddy Lang, Shamir R. Mehta, Christine Papoushek, William Semchuk, Mikul Sharma, Jacob A. Udell, Stephanie LawrenceAnita Mountain, Gord Gubitz, Dar Dowlatshahi, Anne Simard, Andrea de Jong, Eric E. Smith

Institutional Research Division

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Original language	English
Pages (from-to)	E302-E311
Journal	CMAJ
Volume	192
Issue number	12
DOIs	https://doi.org/10.1503/cmaj.191599
Publication status	Published - Mar 23 2020

ASJC Scopus Subject Areas

General Medicine

Access to Document

10.1503/cmaj.191599

Cite this

Wein, T., Patrice Lindsay, M., Gladstone, D. J., Poppe, A., Bell, A., Casaubon, L. K., Foley, N., Coutts, S. B., Cox, J., Douketis, J., Field, T., Gioia, L., Habert, J., Lang, E., Mehta, S. R., Papoushek, C., Semchuk, W., Sharma, M., Udell, J. A., ... Smith, E. E. (2020). Canadian Stroke Best Practice Recommendations, seventh edition: Acetylsalicylic acid for prevention of vascular events. CMAJ, 192(12), E302-E311. https://doi.org/10.1503/cmaj.191599

Wein, T, Patrice Lindsay, M, Gladstone, DJ, Poppe, A, Bell, A, Casaubon, LK, Foley, N, Coutts, SB, Cox, J, Douketis, J, Field, T, Gioia, L, Habert, J, Lang, E, Mehta, SR, Papoushek, C, Semchuk, W, Sharma, M, Udell, JA, Lawrence, S, Mountain, A, Gubitz, G, Dowlatshahi, D, Simard, A, de Jong, A & Smith, EE 2020, 'Canadian Stroke Best Practice Recommendations, seventh edition: Acetylsalicylic acid for prevention of vascular events', CMAJ, vol. 192, no. 12, pp. E302-E311. https://doi.org/10.1503/cmaj.191599

@article{8e854d987e6241909ff745b1110baccd,

title = "Canadian Stroke Best Practice Recommendations, seventh edition: Acetylsalicylic acid for prevention of vascular events",

author = "Theodore Wein and {Patrice Lindsay}, M. and Gladstone, {David J.} and Alexandre Poppe and Alan Bell and Casaubon, {Leanne K.} and Norine Foley and Coutts, {Shelagh B.} and Jafna Cox and James Douketis and Thalia Field and Laura Gioia and Jeffrey Habert and Eddy Lang and Mehta, {Shamir R.} and Christine Papoushek and William Semchuk and Mikul Sharma and Udell, {Jacob A.} and Stephanie Lawrence and Anita Mountain and Gord Gubitz and Dar Dowlatshahi and Anne Simard and {de Jong}, Andrea and Smith, {Eric E.}",

note = "Funding Information: Competing interests: Theodore Wein reports receiving grants from Allergan, Boehringer Ingelheim and Bayer, and grants and consulting fees from Servier, Allergan and Ipsen; conducting accredited continuing medical education sessions for Servier; and receiving travel reimbursement from Servier. David Gladstone reports no personal financial relationships with industry in the 36 months prior to publication. He serves as principal investigator of the SCREEN-AF trial (uncompensated; trial funded by the Canadian Stroke Prevention Intervention Network (C-SPIN), which is funded by the Canadian Institutes of Health Research [CIHR]), and as a national co–principal investigator for the Canadian arm of the ARCADIA trial, which is funded by the National Institutes of Health. Dr. Gladstone previously served as an independent medical safety monitor for that trial (uncompensated); principal investigator of a research grant from the CIHR-funded C-SPIN Network for the Ontario Holter/Echo Database; and a local site investigator for NAVIGATE ESUS, and NASPAF-ICH (all site fees paid to institution). Alexandre Poppe is site principal investigator and site co-investigator for NoNo and Bayer and has received a grant from Canadian Stroke Trials for Optimized Results. Alan Bell reports receving personal fees from AstraZeneca Novartis, Pfizer, Servier and Bayer, outside the submitted work. He is the vice-president of Thrombosis Canada (unpaid position), serves on the board of directors of Hypertension Canada (unpaid position) and was an author of the Antiplatelet Guideline of the Canadian Cardiovascular Society. Leanne K Casaubon reports receiving personal fees from Medtronic and Bayer and is site principal investigator for a clinical trial related to NA1 by NoNo Inc. (no personal financial compensation). James Douketis reports receiving personal fees from Leo Pharma, Janssen, Pfizer, Bristol-Myers Squibb, Sanofi, Servier Canada and Portola, which are deposited in hospital-based (St. Joseph{\textquoteright}s Healthcare Hamilton) and university-based (McMaster University) research accounts or charitable foundations. Dr. Douketis also reports receiving personal fees as an employee of The Merck Manual and UpTo-Date. Thalia Field reports receiving grants and personal fees from Bayer Canada, and personal fees from Pfizer-BMS and Servier, outside the submitted work. Jeffrey Habert reports receiving personal fees from Pfizer, Amgen, BMS, Bayer, Boehringer Ingelheim, Eli-Lilly, Purdue, Allergan, AstraZeneca, Lundbeck, Novo-Nordisk, Servier, Janssen, Roche, HLS, Funding Information: Funding: The development of the Canadian Stroke Best Practice Recommendations is funded in its entirety by the Heart and Stroke Foundation of Canada. No funds for the development of these guidelines are received from commercial interests, including pharmaceutical and medical device companies. Members of the recommendation writing groups and external reviewers are volunteers and do not receive any remuneration for participation in guideline development, updates and reviews.",

year = "2020",

month = mar,

day = "23",

doi = "10.1503/cmaj.191599",

language = "English",

volume = "192",

pages = "E302--E311",

journal = "CMAJ",

issn = "0820-3946",

publisher = "Canadian Medical Association",

number = "12",

}

TY - JOUR

T1 - Canadian Stroke Best Practice Recommendations, seventh edition

T2 - Acetylsalicylic acid for prevention of vascular events

AU - Wein, Theodore

AU - Patrice Lindsay, M.

AU - Gladstone, David J.

AU - Poppe, Alexandre

AU - Bell, Alan

AU - Casaubon, Leanne K.

AU - Foley, Norine

AU - Coutts, Shelagh B.

AU - Cox, Jafna

AU - Douketis, James

AU - Field, Thalia

AU - Gioia, Laura

AU - Habert, Jeffrey

AU - Lang, Eddy

AU - Mehta, Shamir R.

AU - Papoushek, Christine

AU - Semchuk, William

AU - Sharma, Mikul

AU - Udell, Jacob A.

AU - Lawrence, Stephanie

AU - Mountain, Anita

AU - Gubitz, Gord

AU - Dowlatshahi, Dar

AU - Simard, Anne

AU - de Jong, Andrea

AU - Smith, Eric E.

N1 - Funding Information: Competing interests: Theodore Wein reports receiving grants from Allergan, Boehringer Ingelheim and Bayer, and grants and consulting fees from Servier, Allergan and Ipsen; conducting accredited continuing medical education sessions for Servier; and receiving travel reimbursement from Servier. David Gladstone reports no personal financial relationships with industry in the 36 months prior to publication. He serves as principal investigator of the SCREEN-AF trial (uncompensated; trial funded by the Canadian Stroke Prevention Intervention Network (C-SPIN), which is funded by the Canadian Institutes of Health Research [CIHR]), and as a national co–principal investigator for the Canadian arm of the ARCADIA trial, which is funded by the National Institutes of Health. Dr. Gladstone previously served as an independent medical safety monitor for that trial (uncompensated); principal investigator of a research grant from the CIHR-funded C-SPIN Network for the Ontario Holter/Echo Database; and a local site investigator for NAVIGATE ESUS, and NASPAF-ICH (all site fees paid to institution). Alexandre Poppe is site principal investigator and site co-investigator for NoNo and Bayer and has received a grant from Canadian Stroke Trials for Optimized Results. Alan Bell reports receving personal fees from AstraZeneca Novartis, Pfizer, Servier and Bayer, outside the submitted work. He is the vice-president of Thrombosis Canada (unpaid position), serves on the board of directors of Hypertension Canada (unpaid position) and was an author of the Antiplatelet Guideline of the Canadian Cardiovascular Society. Leanne K Casaubon reports receiving personal fees from Medtronic and Bayer and is site principal investigator for a clinical trial related to NA1 by NoNo Inc. (no personal financial compensation). James Douketis reports receiving personal fees from Leo Pharma, Janssen, Pfizer, Bristol-Myers Squibb, Sanofi, Servier Canada and Portola, which are deposited in hospital-based (St. Joseph’s Healthcare Hamilton) and university-based (McMaster University) research accounts or charitable foundations. Dr. Douketis also reports receiving personal fees as an employee of The Merck Manual and UpTo-Date. Thalia Field reports receiving grants and personal fees from Bayer Canada, and personal fees from Pfizer-BMS and Servier, outside the submitted work. Jeffrey Habert reports receiving personal fees from Pfizer, Amgen, BMS, Bayer, Boehringer Ingelheim, Eli-Lilly, Purdue, Allergan, AstraZeneca, Lundbeck, Novo-Nordisk, Servier, Janssen, Roche, HLS, Funding Information: Funding: The development of the Canadian Stroke Best Practice Recommendations is funded in its entirety by the Heart and Stroke Foundation of Canada. No funds for the development of these guidelines are received from commercial interests, including pharmaceutical and medical device companies. Members of the recommendation writing groups and external reviewers are volunteers and do not receive any remuneration for participation in guideline development, updates and reviews.

PY - 2020/3/23

Y1 - 2020/3/23

UR - http://www.scopus.com/inward/record.url?scp=85082761629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85082761629&partnerID=8YFLogxK

U2 - 10.1503/cmaj.191599

DO - 10.1503/cmaj.191599

M3 - Article

C2 - 32392513

AN - SCOPUS:85082761629

SN - 0820-3946

VL - 192

SP - E302-E311

JO - CMAJ

JF - CMAJ

IS - 12

ER -

Canadian Stroke Best Practice Recommendations, seventh edition: Acetylsalicylic acid for prevention of vascular events

ASJC Scopus Subject Areas

Access to Document

Other files and links

Cite this